Amgen announces European approval of Prolia

[News]

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

More... (http://www.news-medical.net/news/20100528/Amgen-announces-European-approval-of-Prolia.aspx)